Eyenovia, Inc. (NASDAQ:EYEN) Q2 2023 Earnings Call Transcript

Michael Rowe: Yes. It’s funny that you asked this question because we just were speaking with some of the technicians at one of the offices in New York. They’ve now used the product for a week. And what they’re finding out is they started by using it on a few patients. They told us today, they used it on every patient, 40 patients they dilated today. And the more they use it, the more they like it. What they’re also finding is that the duration of dilation is less than it is with eye drops, which is actually a positive because one of the reasons people don’t like to get dilated is they end up being dilated for hours and hours and hours, through the rest of the day. And it’s looking like, with Mydcombi, you get the efficacy that you need, and then it may very well not last as long, which is a positive if you get back to normal. So we’re definitely looking into that some more.

Raymond Wu: Appreciate that detail, very helpful. I will jump back in queue. Thanks.

Michael Rowe: Thank you.

Operator: Thank you. I’m showing no further questions at this time. I’d like to hand the floor back to management for any closing comments.

Michael Rowe: Thank you, and thanks, everybody, for joining us today, and that concludes today’s call. We are very pleased with the year we have had so far. We’ve had our first FDA approval and commercial sale of Mydcombi. Our Apersure presbyopia program is progressing, and our manufacturing capabilities are continuing to grow. We look forward to continued momentum through the rest of 2023 and beyond. Thank you again for joining us. We look forward to the third quarter update in [indiscernible].

Operator: Thank you. This does conclude today’s teleconference. We appreciate your participation. You may disconnect your lines at this time. Enjoy the rest of your day.